» Articles » PMID: 35356635

Consensus Statement: Importance of Timely Access to Multiple Myeloma Diagnosis and Treatment in Central America and the Caribbean

Overview
Journal J Hematol
Specialty Hematology
Date 2022 Mar 31
PMID 35356635
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In Central America and the Caribbean, multiple myeloma (MM) patients face significant barriers to diagnosis and treatment. The aim of this study is to describe the current situation of MM in the region, discuss the current barriers to timely diagnosis and proper treatment, and develop consensus recommendations to address these issues.

Methods: Nine experts from five countries took part in a virtual consensus meeting on MM in Central America and the Caribbean. During the meeting, experts analyzed the disease burden, the current conditions for disease management, and access to treatment in the region. The participants reached a consensus on the extent of the problem and the necessary measures.

Results: Hard evidence on the incidence and prevalence of MM in the region is scarce, but the experts perceive an increase in MM cases. The lack of data on the direct and indirect costs at the local and regional levels obscures the impact of the disease and limits awareness among decision-makers. Most patients are diagnosed late and face long waiting times and geographical barriers to access treatment. Access to efficacious innovative therapies that increase survival time is limited due to access barriers within health systems.

Conclusions: There was consensus on five recommendations: 1) to generate evidence; 2) to educate the public; 3) to increase timely diagnosis and facilitate access to treatment; 4) to promote interaction, collaboration, and participation among all sectors involved in the decision-making process; and 5) to guarantee timely access to new therapies.

Citing Articles

Multiple myeloma in Latin America: A systematic review.

Hungria V, Pena C, Gomez-Almaguer D, Martinez-Cordero H, Schutz N, Blunk V EJHaem. 2024; 5(4):867-878.

PMID: 39157594 PMC: 11327730. DOI: 10.1002/jha2.905.


Non-Conventional Allogeneic Anti-BCMA Chimeric Antigen Receptor-Based Immune Cell Therapies for Multiple Myeloma Treatment.

Du Z, Zhu S, Zhang X, Gong Z, Wang S Cancers (Basel). 2023; 15(3).

PMID: 36765526 PMC: 9913487. DOI: 10.3390/cancers15030567.

References
1.
Zhao A, Shen K, Wang J, Huo L, Li J, Cao X . Early or deferred treatment of smoldering multiple myeloma: a meta-analysis on randomized controlled studies. Cancer Manag Res. 2019; 11:5599-5611. PMC: 6595476. DOI: 10.2147/CMAR.S205623. View

2.
Despiegel N, Touboul C, Flinois A, Saba G, Suzan F, Gonzalez-McQuire S . Health-Related Quality of Life of Patients With Multiple Myeloma Treated in Routine Clinical Practice in France. Clin Lymphoma Myeloma Leuk. 2018; 19(1):e13-e28. DOI: 10.1016/j.clml.2018.08.019. View

3.
Pena C, Rojas C, Rojas H, Soto P, Cardemil D, Aranda S . [Survival of 1,103 Chilean patients with multiple myeloma receiving different therapeutic protocols from 2000 to 2016]. Rev Med Chil. 2018; 146(7):869-875. DOI: 10.4067/s0034-98872018000700869. View

4.
Comert M, Gunes A, Sahin F, Saydam G . Quality of life and supportive care in multiple myeloma. Turk J Haematol. 2014; 30(3):234-46. PMC: 3878535. DOI: 10.4274/Tjh.2012.0192. View

5.
Alvarez-Vera J, Aguilar-Luevano J, Alcivar-Cedeno L, Arana-Luna L, Arteaga-Ortiz L, Baez-Islas P . Mexican Consensus on Hodgkin's Lymphoma. Gac Med Mex. 2021; 157(Supl 2):S1-S18. DOI: 10.24875/GMM.M21000500. View